TY - JOUR
T1 - Management of a 75-Year-Old Lady with Refractory Chronic Myelogenous Leukemia
AU - Sobash, Philip T.
AU - Guddati, Achuta K.
AU - Kota, Vamsi
N1 - Publisher Copyright:
© 2020 S. Karger AG. All rights reserved.
PY - 2020
Y1 - 2020
N2 - Chronic myelogenous leukemia (CML) is a hematopoietic disorder caused by the BCR/ABL gene or Philadelphia chromosome. The first Food and Drug Administration (FDA)-approved tyrosine kinase inhibitor for treatment of CML was imatinib in 2001. Since then, multiple therapies, such as nilotinib, dasatinib, bosutinib, and, more recently, ponatinib, have made their way as viable treatment options for first-line and secondary therapies. Most patients tend to respond to first-line treatment. Although there is a subset of patients who do not achieve complete molecular response with first line, newer options have proven beneficial. As we progress through therapies, there still remain some patients who do not adequately respond to current available therapies. The treatment options and guidelines become more difficult in such situations, not only with respect to cost but also patient quality of life and satisfaction. We discuss a 75-year-old white female with CML, who has had multiple therapies with hematological remission but has never achieved complete molecular remission, currently on bosutinib and tolerating it well.
AB - Chronic myelogenous leukemia (CML) is a hematopoietic disorder caused by the BCR/ABL gene or Philadelphia chromosome. The first Food and Drug Administration (FDA)-approved tyrosine kinase inhibitor for treatment of CML was imatinib in 2001. Since then, multiple therapies, such as nilotinib, dasatinib, bosutinib, and, more recently, ponatinib, have made their way as viable treatment options for first-line and secondary therapies. Most patients tend to respond to first-line treatment. Although there is a subset of patients who do not achieve complete molecular response with first line, newer options have proven beneficial. As we progress through therapies, there still remain some patients who do not adequately respond to current available therapies. The treatment options and guidelines become more difficult in such situations, not only with respect to cost but also patient quality of life and satisfaction. We discuss a 75-year-old white female with CML, who has had multiple therapies with hematological remission but has never achieved complete molecular remission, currently on bosutinib and tolerating it well.
KW - Chronic myelogenous leukemia
KW - Complete molecular remission
KW - Major molecular response
KW - Refractory
KW - Tyrosine kinase inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85085213956&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085213956&partnerID=8YFLogxK
U2 - 10.1159/000506895
DO - 10.1159/000506895
M3 - Article
AN - SCOPUS:85085213956
SN - 1662-6575
VL - 13
SP - 534
EP - 537
JO - Case Reports in Oncology
JF - Case Reports in Oncology
IS - 2
ER -